

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM RECEIVED

1648

MAR 0 4 2003

TECH CENTER 1600/2900

(512) 536-4598

GSHISHIMA@FULBRIGHT.COM DIRECT DIAL: (512) 536-3081 TELEPHONE: FACSIMILE:

February 20, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

February 20, 2003

Gina N. Shishima

Commissioner for Patents Washington, D.C. 20231

Re: SN 09/828,498 entitled "FULL-LENGTH GB VIRUS C (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV" by Xiang et al.

Our ref: IOWA:030US/10008943 Client ref: UIRF MO-46

Commissioner:

Please find enclosed the following for filing in the above patent application:

- (1) Response to Office Action Dated November 20, 2002;
- (2) Declaration of Jack T. Stapleton, M.D.; and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:030US.

Very truly yours,

Gina N. Shishima Reg No. 45,104

GNS/lb Enclosures

BEST AVAILABLE COPY

25263998.1